BRAF and neoplasm: The treatment effect of SCH772984 on melanoma has been well confirmed in preclinical xenograft tumor model.454 Besides, the combination of vemurafenib and SCH772984 has been proved to have synergistic effect on suppressing BRAF-mutant melanoma progression, which can help to delay the onset of the resistance to targeted therapy.455 In this case, SCH772984 could be broadly used in a wide variety of melanomas of distinct genetic backgrounds, only if they manifested hyper-activation of ERK signaling.